Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies

Abstract Aims. Arsenic trioxide (As2O3) is increasingly used to treat hematological malignancies. This involves daily intravenous (i.v.) administration for 4–8 weeks, with its attendant drawbacks: inconvenience, risks and expense of maintaining suitable vascular access and hospitalization. We therefore developed an oral formulation, administered it to… CONTINUE READING